New horizons in management of inflammatory bowel disease

International Journal of Pharmacology

Volumn 7, Issue 6, 2011, Pages 679-681

  Salari, Pooneh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIOXIDANT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; ETANERCEPT; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; NANOSELENIUM; NITRIC OXIDE; ONERCEPT; PHOSPHODIESTERASE; PROBIOTIC AGENT; SELENIUM; SILDENAFIL; SILYMARIN; TETOMILAST; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; ARTICLE; COLITIS; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; FISTULIZING CROHN DISEASE; GERMANDER; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; LIPID PEROXIDATION; OXIDATIVE STRESS; REMISSION; SAVORY; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

EID: 80052739309     PISSN: 18117775     EISSN: 18125700     Source Type: Journal    
DOI: 10.3923/ijp.2011.679.681     Document Type: Article

References (29)

1. Abdolghaffari, A.H., A. Baghaei, F. Moayer, H. Esmaily and M. Baeeri etal., 2010. On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. Human Exp. Toxicol., 29: 287-295.
2. Baghaei, A., H. Esmaily, A.H. Abdolghaffari, M. Baeeri, F. Gharibdoost and M. Abdollahi, 2010. Efficacy of setarud (IMOD), a novel drug with potent anti-toxic stress potential in rat inflammatory bowel disease and comparison with dexamethasone and infliximab. Indian J. Biochem. Biophys., 47: 219-226.
3. Ebrahimi, F., H. Esmaily, M. Baeeri, A. Mohammadirad, S. Fallah and M. Abdollahi, 2008. Molecular evidences on the benefit of N-acetylcysteine in experimental colitis. Central Eur. J. Biol. 3: 135-142.
4. Elahi, B., S. Nikfar, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: A meta-analysis of controlled clinical trials. Dig.Dis. Sci.,53: 1278-1284.
5. Elahi, B., S. Nikfar, S. Derakhshani, M. Vafaie and M. Abdollahi, 2009. Benefit of antibiotic therapy on pouchitis after ileal pouch anal anastomosis: A systematic review and meta-analysis of clinical trials. Central Eur. J. Med., 4: 164-170.
6. Esmaily, H., A. Hosseini-Tabatabaei, R. Rahimian, R. Khorasani and M. Baeeri etal, 2009. On the benefits of silymarine in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Cent. Eur. J. Biol., 4: 204-213.
7. Ghazanfari, G., B. Minaie, N. Yasa, L. Ashtaral Nakhai and A. Mohammadirad et al., 2006. Biochemical and histopathological evidences for beneficial effects of Satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol. Mech. Methods, 16: 365-372.
8. Hosseini-Tabatabaei, A. and M. Abdollahi, 2008. Potassium channel openers and improvement of toxic stress: Do they have role in the management of inflammatory bowel disease. Inflamm. Allergy Drug Targets, 7: 129-135.
9. Hosseini-Tabatabaei, A., H. Esmaily, R. Rahimian, R. Khorasani, M. Baeeri and A. Barazesh-Morgani, 2009. Benefit of nicorandil using an immunologic murine model of experimental colitis. Central Euro. J. Biol., 4: 74-85.
10. Jahanshahi, G., V. Motavasel, A. Rezaie, A.A. Hashtroudi, N.E. Daryani and M. Abdollahi, 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci., 49: 1752-1757.
11. Khoshakhlagh, P., M. Bahrololoumi-Shapourabadi, A. Mohammadirad, L. Ashtaral-Nakhai, B. Minaie and M. Abdollahi, 2007. Beneficial effect of phosphodiesterase-5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol. Mech. Methods, 17: 281-288.
12. Miroliaee, A.E., H. Esmaily, A. Vaziri-Bami, M. Baeeri, A.R. Shahverdi and M. Abdollahi, 2011. Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol. Mech. Methods, 21: 200-208.
13. Nikfar, S., R. Rahimi, A. Rezaie and M. Abdollahi, 2009. A Meta-Analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig. Dis. Sci.,54: 1157-1170.
14. Nikfar, S., H. Mirfazaelian and M. Abdollahi, 2010a. Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: A systematic review and meta-analysis of placebo-controlled trials. Curr. Pharm. Des., 16: 3684-3698.
15. Nikfar, S., M. Darvish-Damavandi and M. Abdollahi, 2010b. A review and meta-analysis of the efficacy of antibiotics and probiotics in management of pouchitis. Int. J. Pharmacol., 6: 826-835.
16. Nikfar, S., S. Ehteshami-Afshar and M. Abdollahi, 2011. A systematic review and meta-analysis of the efficacy and adverse events of infliximab in comparison to corticosteroids and placebo in active ulcerative colitis. Int. J. Pharmacol., 7: 325-332.
17. Rahimi, R., S. Nikfar and M. Abdollahi, 2007a. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease: A systematic meta-analysis of controlled clinical trials. Biomed. Pharmacother., 61: 75-80.
18. Rahimi, R, S. Nikfar and M. Abdollahi, 2007b. Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids. Med. Sci. Monit, 13: 13-18.
19. Rahimi, R, S. Nikfar, A. Rezaie and M. Abdollahi, 2007c. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig. Dis. Sci., 52: 2920-2925.
20. Rahimi, R., S. Nikfar, A. Rezaie and M. Abdollahi, 2008a. A meta-analysis of the benefit of probiotics in maintaining remission of human ulcerative colitis: Evidence for prevention of disease relapse and maintenance of remission. Arch. Med. Sci., 4: 185-190.
21. Rahimi, R., S. Nikfar, F. Rahimi, B. Elahi, S. Derakhshani, M. Vafaie and M. Abdollahi, 2008b. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig. Dis. Sci., 53: 2524-2531.
22. Rahimi, R., S. Mozaffari and M. Abdollahi, 2009a. On the use of herbal medicines in management of inflammatory bowel diseases: A systematic review of animal and human studies. Dig. Dis. Sci., 54: 471-480.
23. Rahimi, R., S. Nikfar, A. Rezaie and M. Abdollahi, 2009b. Comparison of mesalazine and balsalazide in induction and maintenance of remission inpatients with ulcerative colitis: A meta-analysis. Dig. Dis. Sci., 54: 712-721.
24. Rahimi, R., M.R. Shams-Ardekani and M. Abdollahi, 2010. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J. Gastroenterol., 16: 4504-4514.
25. Rezaie, A., B.T. Bayat and M. Abdollahi, 2005. Biologic management of fistulizing Crohn's disease. Int. J. Pharmacol., 1: 17-24.
26. Rezaie, A., F. Ghorbani, A. Eshghtork, M. J. Zamani and G. Dehghan, et at, 2006. Alterations in salivary antioxidants, nitric oxide and transforming growth factor-[3l in relation to disease activity in Crohn's disease patients. Ann. N. Y. Acad. Sci., 1091: 110-122.
27. Rezaie, A., R.D. Parker and M. Abdollahi, 2007a. Oxidative stress and pathogenesis of inflammatory bowel disease: An epiphenomenon or the cause. Dig. Dis. Sci., 52: 2015-2021.
28. Rezaie, A., S. Khalaj, M. Shabihkhani, S. Nikfar, M.J. Zamani, A. Mohammadirad and N.E. Daryani 2007b. Study on the correlations among disease activity index and salivary transforming growth factor-[3l and nitric oxide in ulcerative colitis patients. Ann. N.Y. Acad. Sci., 1095: 305-314.
29. Salari-Sharif, P. and M. Abdollahi, 2010. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: A comprehensive review. Curr. Pharm. Des., 16: 3661-3667.